Mark David Linch
University College London Hospitals NHS Foundation Trust · 166 works · 4,210 citations · h-index 31
Top works
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
- Response Rate to Chemotherapy After Immune Checkpoint Inhibition in Metastatic Urothelial Cancer
- 1397P Phase I results of exicorilant plus enzalutamide in patients with castration-resistant prostate cancer
- PKC and the control of localized signal dynamics
- Systemic treatment of soft-tissue sarcoma—gold standard and novel therapies
- Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder
- Determinants of anti-PD-1 response and resistance in clear cell renal cell carcinoma
- Durvalumab in combination with BCG for BCG-naive, high-risk, non-muscle-invasive bladder cancer (POTOMAC): final analysis of a randomised, open-label, phase 3 trial
- Molecular and histopathology directed therapy for advanced bladder cancer
- Clinical Activity and Tolerability of a 14-Day Infusional Ifosfamide Schedule in Soft-Tissue Sarcoma
- A phase II study investigating the safety and efficacy of neoadjuvant atezolizumab in muscle invasive bladder cancer (ABACUS).
- Novel therapeutic agents in ovarian cancer
- Atypical Protein Kinase Cι as a human oncogene and therapeutic target
- mTORC2 targets AGC kinases through Sin1-dependent recruitment
- Protein kinase C intervention—the state of play
- A Cancer-Associated Mutation in Atypical Protein Kinase Cι Occurs in a Substrate-Specific Recruitment Motif
- Control of MT1-MMP transport by atypical PKC during breast-cancer progression
- Representative Sequencing: Unbiased Sampling of Solid Tumor Tissue
- Intratumoural evolutionary landscape of high-risk prostate cancer: the PROGENY study of genomic and immune parameters
- Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study